[en] The goal of the TREAT study is to estimate the prevalence of true resistant hypertension in a Belgian setting of patients with apparent treatment resistant hypertension (aTRH) and to evaluate which determining factor of pseudo-resistant hypertension contributes the most to this prevalence. TREAT is a single-visit, multicentric, non-interventional, cross-sectional survey. Inclusion criteria included: patients over 18 years receiving 3 or more antihypertensive molecules and referred to specialized hospital centers for aTRH. A total of 201 eligible patients were included. Only 56.7% of the patients were treated with the guideline recommended triple combination therapy (i.e. renin-angiotensin-aldosterone system inhibitor, calcium channel blocker and thiazide (-like) diuretic), and only 23.4% were treated with the maximal recommended dose. WCH was present in 8.7% of the 115 patients with available ambulatory blood pressure recordings. Therapeutic adherence was self-reported as good by 80% of patients, while 20% reported poor or moderate adherence. In this cohort, the prevalence (95% CI) of true resistant hypertension was estimated at 21.9% (14.7%-30.6%). Among patients referred to specialized centers for aTRH, about 3 out of 4 presented with pseudo-resistant hypertension. The occurrence of WCH and poor adherence appeared rather limited in our study, but half of the participants were polymedicated with non-recommended combinations of antihypertensive molecules. Inadequate dosing was observed in the majority of patients and a third was not using a single pill combination. Hence, pseudo-resistant hypertension seems to be mainly associated with the underuse of triple combination therapy and, most likely, with suboptimal dosing.
Disciplines :
Urology & nephrology
Author, co-author :
Brouwers, Sofie; Cardiovascular Center Aalst, AZORG Clinic Aalst, Aalst, Belgium ; Department of Experimental Pharmacology, Vrije Universiteit Brussel, Brussels, Belgium
Huart, Justine ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Chabot, Mathilde; Servier, Brussels, Belgium
Van Nieuwenhuyse, Bregt; Servier, Brussels, Belgium
De Bacquer, Dirk; Department of Public Health and Primary Care, Ghent University, Ghent, Belgium
Munhoz, Daniel; Cardiovascular Center Aalst, AZORG Clinic Aalst, Aalst, Belgium ; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy
Language :
English
Title :
TREAT: A Multicentre Cross-sectional TReatment Evaluation of Apparent Resistant hyperTension in Belgium.
This study was funded by Servier BeLux. The sponsor had no role in the data analysis or interpretation, which were performed independently by the investigators.
World Health Global report on hypertension. The Race Against a Silent Killer, WHO, 2023, https://www.who.int/publications/i/item/9789240081062.
D. Ettehad, C. A. Emdin, A. Kiran, et al., “Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-analysis,” Lancet 387 (2016): 957–967.
J. D. Bundy, C. Li, P. Stuchlik, et al., “Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis,” JAMA Cardiology 2, no. 7 (2017): 775–781.
K. Rahimi, Z. Bidel, M. Nazarzadeh, et al., “The Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological Blood Pressure Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure: An Individual Participant-level Data Meta-analysis,” Lancet 397 (2021): 1625–1636.
B. Williams, G. Mancia, X. Spiering, et al., “2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH),” European Heart Journal 39 (2018): 3021–3104.
G. Mancia, R. Kreutz, M. Brunström, et al., “2023 ESH Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA),” Journal of Hypertension 41, no. 12 (2023): 1874–2071.
J. W. McEvoy, C. P. McCarthy, R. M. Bruno, et al., “ESC Scientific Document Group. 2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension,” European Heart Journal 45, no. 38 (2024): 3912–4018.
W. Vongpatanasin, “Resistant Hypertension: A Review of Diagnosis and Management,” Jama 311 (2014): 2216–2224.
R. M. Carey, S. Sakhuja, D. A. Calhoun, P. K. Whelton, and P. Muntner, “Prevalence of Apparent Treatment-Resistant Hypertension in the United States,” Hypertension 73 (2019): 424–431.
R. Alsharari, E. Shantsila, G. Y. H. Lip, and A. Shantsila, “Revisiting the Diagnosis of 'Resistant Hypertension': What Should We Do Nowadays,” Journal of Human Hypertension 36, no. 4 (2022): 337–340.
E. Judd and D. A. Calhoun, “Apparent and True Resistant Hypertension: Definition, Prevalence and Outcomes,” Journal of Human Hypertension 28, no. 8 (2014): 463–468.
M. T. Kim, M. N. Hill, L. R. Bone, and D. M. Levine, “Development and Testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale,” Progress in Cardiovascular Nursing 15, no. 3 (2000): 90–96.
J. J. Noubiap, J. R. Nansseu, U. F. Nyaga, P. S. Sime, I. Francis, and J. J. Bigna, “Global Prevalence of Resistant Hypertension: A Meta-Analysis of Data From 3.2 Million Patients,” Heart 105, no. 2 (2019): 98–105.
J. J. Sim, S. K. Bhandari, J. Shi, et al., “Characteristics of Resistant Hypertension in a Large, Ethnically Diverse Hypertension Population of an Integrated Health System,” Mayo Clinic Proceedings 88, no. 10 (2013): 1099–1107.
R. R. Townsend and J. B. Cohen, “White Coat Hypertension & Cardiovascular Outcomes,” Current Hypertension Reports 26, no. 10 (2024): 399–407, https://doi.org/10.1007/s11906-024-01309-0.
C. Tomasino and M. Tomasino, “Medication Adherence and Non-Adherence in Arterial Hypertension: A Narrative Review,” Exploration of Medicine 6 (2025): 1001276.
